Pharma channel feed

Sarep­ta's Ex­ondys 51 is not cost-ef­fec­tive, nor par­tic­u­lar­ly ben­e­fi­cial for DMD pa­tients — ICER

7 years ago
R&D

No­var­tis chief Vas Narasimhan wants you to know about the '25-plus’ block­busters he has in the pipeline

7 years ago
R&D

An­oth­er Eli Lil­ly on­col­o­gy drug is in trou­ble, as Japan is­sues Verzenio safe­ty warn­ing

7 years ago

Drug reg­u­la­tors look to har­mo­nize how they tack­le in­no­va­tion

7 years ago
R&D
FDA+

Roche's Chugai to set up new $1B+ lab in Yoko­hama, con­sol­i­dat­ing R&D

7 years ago
R&D

Thanks to Supreme Court de­ci­sion, Mer­ck gets an­oth­er chance to throw out Fos­amax claims

7 years ago

Google's life sci­ences sis­ter plugs Big Phar­ma in­to the main­stream in a dig­i­tal over­haul of the clin­i­cal tri­al busi­ness

7 years ago

BioCryst shares are blast­ed as a PhI­II HAE 'suc­cess' un­der­whelms an­a­lysts

7 years ago
R&D

Be­lea­guered Bio­gen faces the mu­sic as a ris­ing cho­rus of crit­ics push for a trans­for­ma­tive ap­proach to M&A

7 years ago
Deals

Mer­ck bets $2.2B on a small can­cer drug biotech, snatch­ing it out of the IPO line­up

7 years ago
Deals
R&D

Mer­ck­'s Keytru­da fails triple neg­a­tive breast can­cer piv­otal study

7 years ago

TRC Cap­i­tal's mi­ni-ten­der of­fer ir­ri­tates a flus­tered Bio­gen

7 years ago

Can­cer re­search groups urge FDA to over­haul stan­dards for ear­ly cell ther­a­py tri­als, cut­ting time and cost. But will 'pre-com­pet­i­tive' al­liances fly?

7 years ago
R&D
Cell/Gene Tx

Un­der fire for Tru­va­da US pric­ing at House hear­ing, Gilead chief O'­Day touts R&D costs, as­serts gov­ern­ments patents are void

7 years ago

EMA im­pos­es for­mal lim­it on Xel­janz pre­scrip­tion as reg­u­la­tors con­tin­ue to re­view safe­ty con­cerns

7 years ago

Fol­low­ing its lat­est set­back, Achillion posts some en­cour­ag­ing PoC da­ta for lead drug

7 years ago
R&D

Take­da, Fra­zier cre­ate Phath­om Phar­ma­ceu­ti­cals to spur de­vel­op­ment of GI drug vono­prazan in $140M play

7 years ago

Four years af­ter EU ap­proval, NICE fi­nal­ly backs Revlim­id use in cer­tain first-line mul­ti­ple myelo­ma pa­tients

7 years ago

Af­ter a long march with Cabo, Ex­elix­is is ex­pand­ing its fo­cus with an an­ti­body-drug con­ju­gate deal

7 years ago
R&D

An­a­lysts spot­light the win­ners — and losers — on AS­CO pre­view night

7 years ago
R&D

J&J pol­ish­es up its new list of late-stage block­buster can­di­dates — and can­cer re­mains big

7 years ago
R&D

Im­muno­Gen shares tank (again) af­ter the FDA nix­es a shot at an OK for its armed an­ti­body in wake of a failed PhI­II

7 years ago
R&D

Pfiz­er, Mer­ck KGaA clinch need­ed ap­proval for Baven­cio, di­rect­ly com­pet­ing against Keytru­da in kid­ney can­cer

7 years ago

Al­most half of all new drug ap­provals in 2018 re­lied on one clin­i­cal tri­al

7 years ago
FDA+
First page Previous page 272273274275276277278 Next page Last page
A service from the Financial Times